那他珠单抗辅助治疗耐药性癫痫的2期研究:安全性与疗效
主要终点未达到预设疗效阈值:那他珠单抗组相对安慰剂组癫痫发作频率估计相对变化为-14.4%(95%CI -46.1%-36.1%;p=0.51)。安全性方面无意外发现,研究提示需进一步探索抗炎治疗用于耐药性癫痫。
要点
- 那他珠单抗每4周静脉注射未显著降低耐药性局灶性癫痫发作频率。
- 那他珠单抗组与安慰剂组不良事件发生率分别为75%和65%,无意外安全性发现。
- 研究精度不足,无法排除那他珠单抗的重要疗效。
核心结论
- 那他珠单抗300 mg每4周静脉注射辅助治疗成人耐药性局灶性癫痫,未达到预设的疗效阈值。
- 研究未发现意外安全性问题,但研究精度不足以排除重要疗效。
研究设计与样本
- 2期随机双盲安慰剂对照研究,纳入6周基线期内癫痫发作≥6次的成人耐药性局灶性癫痫患者。
- 患者按1:1随机接受那他珠单抗300 mg静脉注射或安慰剂,每4周一次,共24周。
- 那他珠单抗组32例和安慰剂组34例接受给药,分别有30例(94%)和31例(91%)完成安慰剂对照治疗期。
主要发现
- 那他珠单抗相对安慰剂组癫痫发作频率的估计相对变化为-14.4%(95%CI -46.1%-36.1%;p=0.51)。
- 那他珠单抗组癫痫发作频率较基线降低≥50%的比例为31.3%,安慰剂组为17.6%(OR 2.09,95%CI 0.64-6.85;p=0.22)。
- 不良事件发生率那他珠单抗组为75%(24例),安慰剂组为65%(22例)。
关键数值与推荐
- 主要疗效终点为log转换后癫痫发作频率较基线的变化,预设治疗成功阈值为相对安慰剂组癫痫发作频率相对降低31%。
- 可计数发作类型包括伴运动体征的局灶性知觉发作、局灶性知觉受损发作和局灶继发双侧强直阵挛发作。
临床怎么用
- 当前证据不支持那他珠单抗用于成人耐药性局灶性癫痫的常规辅助治疗。
- 该研究提示可进一步探索抗炎治疗用于耐药性癫痫,但需更大样本研究验证。
局限性
- 研究样本量小,缺乏排除重要疗效的精度。
- 研究未达到预设疗效阈值,主要终点为阴性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To explore efficacy/safety of natalizumab, a humanized monoclonal anti-α4-integrin antibody, as adjunctive therapy in adults with drug-resistant focal epilepsy. METHODS: Participants with ≥6 seizures during the 6-week baseline period were randomized 1:1 to receive natalizumab 300 mg IV or placebo every 4 weeks for 24 weeks. Primary efficacy outcome was change from baseline in log-transformed seizure frequency, with a predefined threshold for therapeutic success of 31% relative reduction in seizure frequency over the placebo group. Countable seizure types were focal aware with motor signs, focal impaired awareness, and focal to bilateral tonic-clonic. Secondary efficacy endpoints/safety were also assessed. RESULTS: Of 32 and 34 participants dosed in the natalizumab 300 mg and placebo groups, 30 (94%) and 31 (91%) completed the placebo-controlled treatment period, respectively (one participant was randomized to receive natalizumab but not dosed due to IV complications). Estimated relative change in seizure frequency of natalizumab over placebo was -14.4% (95% confidence interval [CI] -46.1%-36.1%; p = 0.51). The proportion of participants with ≥50% reduction from baseline in seizure frequency was 31.3% for natalizumab and 17.6% for placebo (odds ratio 2.09, 95% CI 0.64-6.85; p = 0.22). Adverse events were reported in 24 (75%) and 22 (65%) participants receiving natalizumab vs placebo. DISCUSSION: Although the threshold to demonstrate efficacy was not met, there were no unexpected safety findings and further exploration of possible anti-inflammatory therapies for drug-resistant epilepsy is warranted. TRIAL REGISTRATION INFORMATION: The ClinicalTrials.gov registration number is NCT03283371. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that IV natalizumab every 4 weeks, compared to placebo, did not significantly change seizure frequency in adults with drug-resistant epilepsy. The study lacked the precision to exclude an important effect of natalizumab.
引用
- French JA, Cole AJ, Faught E, et al. Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study. Neurology. 2021. PMID: 34521687. doi:10.1212/WNL.0000000000012766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。